Odylia CSO speaks to the Charles River World Congress
Odylia CSO Harrison Brown speaks to the Charles River World Congress on the promises and challenges of gene therapy for rare diseases. Video link: Delivering the DNA...
01 November, 2018
Odylia CEO speaks at NIH/NCATS conference (video)
Odylia CEO Scott Dorfman presented the Odylia concept to the National Institutes of Health and National Center for Advancing Translational Sciences (NCATS) at a conference on The Growing Promise of Gene Therapy Approaches. Please skip to 4:18:00 to see the Odylia talk and followup panel discussion. Please click...
20 September, 2018
Odylia and co-founder Luk Vandenberghe have been named Xconomy Contrarian Awards finalists
Odylia and co-founder Luk Vandenberghe have been named Xconomy Contrarian Awards finalists After decades of ups and downs, gene therapy’s renaissance is well underway. With one gene therapy, Luxturna, now approved in the U.S., several more are advancing through clinical testing. It’s standard fare now to...
27 August, 2018
Odylia and Aldevron partner to help more people see
Aldevron and Odylia partner for gene therapy treatments of ultra-rare diseases. Odylia and Aldevron, a contract manufacturing organization specializing in the production of plasmid DNA and other biological agents, have entered into an agreement in which Aldevron is a member of Odylia. Under this agreement, Aldevron...
27 June, 2018
Odylia CEO to speak at the International Symposium on Usher Syndrome
Odylia will be attending the International Symposium on Usher Syndrome July 19-21 in Mainz, Germany. CEO, Scott Dorfman, will be speaking during the scientific presentations on July 20 to present Odylia’s mission to move science to the clinic. Odylia will also present a poster at the...
30 May, 2018
Odylia to attend ASGCT 2018
Odylia will be attending the 2018 Annual Meeting of the American Society of Gene and Cell Therapy. We will be meeting with companies and individuals to discuss ways an Odylia partnership can quickly advance therapies for rare disease from the lab to the clinic. Visit Website...
15 May, 2018
Odylia CEO speaks to RARECast about Odylia’s mission
Scott Dorfman, co-founder and CEO of Odylia, speaks to RARECast about what drove the creation of Odylia, how it works as a non-profit, and how we can extend our model to bring more therapies for rare disease to patients. Listen to Interview...
02 April, 2018
Odylia co-founder Mass Eye performs first post-approval injection of Luxturna®
Massachusetts Eye and Ear says it has performed the first post-approval injection of the Luxturna®, which treats a form of blindness caused by RPE65 deficiency, otherwise known as RP20. The hospital announced on Tuesday that Jason Comander, the associate director of its inherited retinal disorders...
22 March, 2018
Odylia speaks to Xconomy about our plan to resurrect stranded gene therapies
Odylia co-founders Scott Dorman and Luk Vandenberghe speak to Xconomy about the problems keeping gene therapies for rare disease from reaching patients. In this article, Dorfman and Vandenberghe speak about the dozens, if not hundreds, of inherited retinal dystrophies that could be amenable to treatment...
07 March, 2018
Odylia to attend Gene Therapy for Rare Disorders 2018
Odylia will be attending the second annual Gene Therapy for Rare Disorders conference in Boston. We will be speaking to companies and individuals about how Odylia can accelerate the development of gene therapies for rare disorders. Visit Website...
05 March, 2018